MedTrace Logo

A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMD

NCT01242254 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-03-27

No results posted yet for this study

Summary

This study is designed to assess the efficacy and safety of multiple intravitreal injection of KH902 in patients with CNV due to AMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL

Intravitreal injection of KH902

0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase

Sponsors & Collaborators

  • University of Wisconsin, Madison

    collaborator OTHER

  • Air Force Military Medical University, China

    collaborator OTHER

  • Chengdu Kanghong Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Junjun Zhang · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-03-31
Completion
2011-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01242254 on ClinicalTrials.gov